and agarciag@carrerasresearch.org Running title: Reverting DNA methylation to treat MM bone disease Abbreviations: mesenchymal stromal cells, osteoblast, multiple myeloma, DNA methylation Abstract word count: 212 Word count: 3999 Figure count: 5 Reference count: 60 ABSTRACT Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on the bone marrow (BM) microenvironment, in particular on mesenchymal stromal cells (MSCs). MSCs from MM patients exhibit an abnormal transcriptional profile, suggesting that epigenetic alterations could be governing the tumor-promoting functions of MSCs and their prolonged osteoblast (OB) suppression in MM. In this study, we analyzed the DNA methylome of BM-derived MSCs from patients with monoclonal gammopathy of undetermined significance, smoldering myeloma and symptomatic MM at diagnosis in comparison with their normal counterparts. DNA methylation alterations were found at each of the myeloma stage in association with deregulated expression levels of Homeobox genes involved in osteogenic differentiation. Moreover, these DNA methylation changes were recapitulated in vitro by exposing MSCs from healthy individuals to MM plasma cells. Pharmacological targeting of DNMTs and G9a with the dual inhibitor CM-272, reverted the expression of aberrantly methylated osteogenic regulators and promoted OB differentiation of MSCs from myeloma patients. Most importantly, in a mouse model of bone marrow-disseminated MM, administration of CM-272 prevented tumor-associated bone loss and reduced tumor burden. Our results demonstrated that not only was aberrant DNA methylation a main contributor to bone formation impairment found in MM patients, but also its targeting by CM-272 was able to reverse MM-associated bone loss.
KEY POINTS:
-Bone marrow-derived mesenchymal stromal cells (MSCs) from monoclonal gammopathy of undetermined significance, smoldering myeloma and myeloma patients exhibit an aberrant DNA methylome compared to their healthy counterparts.
-These DNA methylation changes are associated with an altered expression of genes of the Homeobox loci that orchestrate osteogenic differentiation of mesenchymal precursors.
-MM plasma cell-exposed healthy MSCs recapitulate the DNA methylation alterations observed in MSCs isolated from myeloma patients.
-Dual targeting of DNMTs and the histone methyltransferase G9a with CM-272 not only controls MM tumor burden but also prevents myeloma-associated bone loss.
INTRODUCTION
Multiple myeloma (MM) is an incurable hematological malignancy of clonal expansion of plasma cells in the bone marrow (BM) that accounts for 1% of all cancers 1 2 . Nearly 90% of myeloma patients suffer from skeletal related events during the course of the disease, including severe bone pain, hypercalcemia, pathological fractures and spinal cord compression 3 , that not only affect the quality of life but also the overall survival of MM patients 4 . Myeloma-associated bone disease (MBD) is characterized by an increase in bone-resorptive activity and number of osteoclasts (OCs), as well as impairment of bone-forming activity and differentiation of osteoblasts (OBs), which ultimately lead to the development of osteolytic lesions 5 .
In most cases, symptomatic myeloma is preceded by sequential asymptomatic stages of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM), with increasing BM plasmocytosis and monoclonal component as well as augmented risk of progression to active MM 67 . The biological behavior and clinical outcome of MM is partly dependent on genetic and epigenetic abnormalities of tumor subclones that arise from MGUS and SMM stages 8 . However, the clinical stability of MGUS cases, despite displaying shared genetic lesions with MM cells, suggests that the BM microenvironment may critically regulate disease progression 9610 . In this regard, it has been widely shown that a complex and bidirectional relationship exists between MM cells and the BM niche, which results in oncogenesis support, anaemia, immunosuppression and uncoupling of the bone remodeling process 11 .
Mesenchymal stromal cells (MSCs) are an essential cell type in the formation and function of the BM microenvironment, being the progenitors of bone-forming OBs, adipocytes and chondroblasts, as well as the haematopoietic-supporting stroma components of the BM 12 . It is well-documented that BM-derived MSCs from MM patients contribute to MM progression (reviewed in 11 ) and show an impaired ability to differentiate into OBs 1314 . Moreover, MM-MSCs are considered inherently abnormal, as their dysfunctionality remains even following ex vivo culture in the absence of MM cells 15 . Furthermore, bone lesions persist in many MM patients even after therapeutic remission, suggesting a long-term defect in MSCs that inhibit their ability to properly differentiate into functional OBs 16 .
Previous studies described that MSCs from MM patients are cytogenetically normal 17 18 , but show alterations in their transcriptional 13 19 and proteomic 11 profiles even in the absence of myeloma cell interaction. This suggests that epigenetic mechanisms could be governing the tumor-promoting functions of MSCs and their prolonged OB suppression in MM. In fact, Adamik and colleagues reported an abnormal recruitment of chromatin remodelers in MSCs from myeloma patients, contributing to the transcriptional repression of Runx2, a master regulator of OB differentiation 20 . Yet, there is a lack of information about DNA methylation-based mechanisms that may contribute to MM progression and subsequent bone defects. DNA methylation is an essential epigenetic modification involving the addition of a methyl group to the 5-carbon of the cytosine ring by a family of DNA methyltransferase (DNMT) enzymes 21 , which has been described to play a critical role in MSC lineage determination 22 , as well as in tumor progression and immunosuppression in other cancer types 23 ..
In this study, we aimed to determine the DNA methylome of BM-derived MSCs in the context of MM, since not only would they play an essential role in OB differentiation but would also perpetuate an aberrant functional state of the BM niche and drive disease progression. We identified DNA methylation alterations in MSCs and the ability of MM plasma cells to induce such changes, which result in the dysregulation of critical genes for osteogenesis. Finally, we explored the in vitro and in vivo preclinical efficacy of CM-272, a dual inhibitor of DNMTs and the histone methyltransferase G9a, which cooperates closely with DNA methylation, in the context of MBD.
Participants
BM samples were obtained from patients with newly diagnosed MGUS (n = 10), SMM (n = 8), and MM (n = 9), according to the International Myeloma Working Group criteria. BM samples from healthy controls (n=8) were obtained from participants undergoing orthopedic surgery. Each sample was obtained after receiving informed written consent of all participating subjects and following approval from the University Hospital of Salamanca de Salamanca Review Board. Clinical characteristics of MGUS, SMM and MM patients are listed in Supplementary Table S1 .
Statistical analysis
DNA methylation and transcriptomic array analyses were performed using the R environment, in which a student t test was used to determine statistically significant differences between groups. Each in vitro assay was performed using MSCs from at least three donors. Data are expressed as mean ± SEM. Statistical analyses were carried out with Prism version 6.0 (GraphPad) and were performed using a two-tailed Mann-Whitney U test or Student´s t test.
Information regarding reagents, cells, methylation/sequencing/bioimaging platforms, molecular biology techniques and in vivo studies are described in Supplementary Methods.
RESULTS

BM-derived MSCs of distinct MM stages exhibit altered DNA methylation profiles
We first obtained genome-wide DNA methylation profiles of BM-derived MSCs isolated at different stages of MM (newly diagnosed MGUS, high-risk SMM and MM) and healthy controls. DNA methylation changes were identified using two different statistical approaches ( Figure 1A) : i) detection of differentially methylated CpG positions (DMPs) based on differences in DNA methylation means between patient (MGUS, SMM and MM) and healthy MSCs (Δβ ≥ 0.15 and **p < 0.01) Table S2 ); and ii) detection of differentially variable CpG positions (DVPs) based on differences in variance of DNA methylation levels (FDR < 0.05 and *p < 0.05) between the sample groups ( Supplementary Table S3 ). In regards to DMPs, the largest number of altered CpGs was found in the SMM stage compared to healthy donors (Supplementary Figure S1A and S1B). On the other hand, we observed the highest number of DVPs in MGUS followed by SMM and MM samples (Supplementary Figure S1C and 1D) , supporting the notion that these stochastic and heterogeneous DNA methylation patterns are associated with early stages of carcinogenesis, as previously reported 2425 . We also observed that the majority of identified DMPs and DVPs are disease stage-specific, although the asymptomatic stages showed a moderate proportion of overlap ( Figure   1A ).
(Supplementary
Given that myeloma is a multi-stage disease, we then analyzed the accumulative changes of DNA methylation associated to MM progression by selecting DMPs and DVPs that were found either only in MM stage, shared by SMM and MM and in all three stages (574 hyper-and 682 hypomethylated CpGs) ( Figure 1A) ( Supplementary Table S4 ).
Analyzing the distribution of MM progression-associated CpGs in relation to CpG islands (CGI), we observed a significant enrichment of CpG islands in the hypermethylated CpG set ( Figure   1B ). Utilizing publicly available chromatin state maps of BM-derived MSCs from healthy individuals 26 , we found a significant enrichment of both hyper-and hypo-methylated CpG sites that correspond to enhancers ( Figure 1C ). In addition, we observed an enrichment in flanking transcription start sites (TSS) in the hypomethylated set, and bivalent TSS and Polycomb Group (PcG) genes in hypermethylated CpGs ( Figure 1C ).
To determine whether these MM progression-associated loci shared any common DNA elements, we performed a search for enriched transcription factor (TF)-binding sites in these regions using the HOMER algorithm 27 . We observed a significant over-representation of binding sites for Runt and Tead family in differentially hyper-methylated regions associated to MM progression (**p<0.01; Figure 1D ). These results suggest that key transcription factors involved in the upregulation of osteogenic genes, such as RUNX2 28 or TEAD2 29 , might participate in aberrant DNA hypermethylation. Since DNA methylation has been originally linked to transcriptional repression, these results suggested that the hypermethylation of these regions could compromise the ability of MSCs to undergo proper differentiation. On the other hand, CpG sites that experience aberrant DNA hypomethylation were highly enriched in binding motifs of the bZip and Homeobox families (**p<0.01; Figure 1D ). In this respect, the loss of DNA methylation could be selectively driving the occupancy of TF that have been reported as negative regulators of OB differentiation such as HOXA2 30 and ATF3 31 . In addition, we observed transcriptional deregulation of some members of these TF families using expression array data from BM-derived MSCs of healthy controls, MGUS, SMM and MM patients.
Some of these TFs were specifically downregulated in MSCs of active myeloma (RUNX2 and TEAD2), whereas others were already downregulated in precursor myeloma stages (HOXC9 and CEBPD) (Supplementary Figure S1E) . In all, these findings suggested that MM progressionassociated DNA methylation changes in MSCs were mediated by the sequential activity of specific TF families, which were also functionally deregulated in MM 32 . Furthermore, other genes that play important roles in the pathophysiology of MM (such as the cytokines IL6 and OSM) and associated MBD (secreted factors such as RANKL, SFRP2, IL7, CHSY1 and the transcriptional repressor GFI1)
were also found to alter their DNA methylation levels ( Figure 1E ).
Aberrant DNA methylation is associated with differential Homeobox gene expression in MSCs at different MM stages
To further investigate the relationship between differential DNA methylation and gene expression, we mapped the DMPs and DVPs ( Supplementary Table S2 and S3) to the most proximal gene. Using expression array data from BM-derived MSCs of healthy controls, MGUS, SMM and MM patients ( Supplementary Table S5 ), differential expression of DMP-and DVP-associated genes were identified using a cutoff of *p < 0.05 comparing MGUS/SMM/MM to healthy controls ( Figure 2A) ( Supplementary Table S6 ). Gene ontology (GO) analysis revealed that the genes displaying both differential methylation and expression were enriched in functional categories important in cell fate commitment and bone phenotype ( Figure 2B ). The most enriched functional category corresponded to genes from the Homeobox family. Within the Homeobox family, we found the subset of Hox genes that encodes a large family of highly conserved TFs responsible for driving the correct differentiation of MSCs 33 , namely genes belonging to the HOXA-to-D clusters. Furthermore, we observed a significant enrichment in genes reported to be downregulated in MM-MSCs ( Figure 2B ) 13 . Integration of methylation and gene expression data corresponding to the Homeobox and bone formation-related genes revealed that both DNA hyper-and hypo-methylation events were associated with both gene downregulation and upregulation ( Figure 2C) . Specifically, hypermethylated genes that showed a reduced expression in patient MSCs include positive regulators of OB differentiation such as RUNX2 or NRP2 34 ( Figure 2C ) In contrast, negative regulators of osteogenesis such as SFRP2 35 or NFATC2 36 were hypomethylated and consequently upregulated in patient MSCs. In all, these factors could potentially contribute to impaired osteoblastogenesis associated to bone disease in MM and this is summarized in Supplementary Table S7 ).
Upon a closer inspection of several Homeobox-associated genomic regions, we observed a negative correlation between DNA methylation of promoters and gene expression. Specifically, HOXA gene cluster showed aberrant hypo-methylation at the HOXA4 promoter, and its gene expression was upregulated at different disease stages. Conversely, gene promoters of HOX-A6, -A7, -A9, -A10 and 2D) (Supplementary Figure S2) . A similar pattern of inverse association between methylation and expression was observed in the HOXB and HOXC gene cluster, where HOXB5, -B6, -C5 and -C8
were aberrantly hypomethylated and upregulated, whereas HOXC9, -C10 and -C11 were hypermethylated and downregulated in patients ( Figure 2D) (Supplementary Figure S2) . Other Homeobox genes such as TBX5, PITX1 or EMX2 were also reported as regulators of bone formation 373839 and showed an association between DNA methylation at gene promoter and gene expression ( Figure 2D) (Supplementary Figure S2) .
We then validated the aforementioned DNA methylation and gene expression changes in an independent cohort of BM-derived MSCs from different MM disease stages by pyrosequencing and real-time quantitative PCR assays. Among the differentially methylated genes of the Homeobox family, we selected HOXA2, -A4 and -C10 on the basis of their reported role in MSC pluripotency 40 .
In all cases, we observed that DNA methylation negatively correlated with gene expression ( Figure   2E ). We then investigated the DNA methylation profiling of MSCs from healthy donors generated upon interaction with MM cells. We observed that 142 CpGs that change their methylation levels upon co-culture with MM.1S cells were shared with aberrant DNA profiles found in MSCs isolated from MGUS/SMM/MM patients ( Figure 3D ; Supplementary Table S8 ). Although this accounted for a small percentage of DMPs identified in the in vitro study, GO analyses revealed an enrichment in Homeobox genes and categories related with bone formation, similar to what was observed in primary patient MSCs ( Figure 3E ). Specifically, we found that healthy MSCs exposed to MM cells underwent gains (HOXA9, ACVR2A, EBF2) and losses (HOXA2, HOXA3, HOXC5) of DNA methylation in the direction of those observed for MSCs from myeloma patients ( Figure 3F) . Altogether, these results support the notion that MM cells not only are capable of inducing changes in the global methylome of MSCs but also have a significant impact at specific osteogenic loci.
Upon interaction with MM plasma cells, healthy MSCs change their DNA methylation profile to one that partially resembles MM patients upon interaction with MM plasma cells
Dual targeting of DNMTs and G9a restores Homeobox gene expression in vitro and promotes osteogenic differentiation of mesenchymal precursors
Gene expression analysis of DNMTs in MSCs from HD and MM patients co-cultured with MM cells obtained from a previous study 41 showed an aberrant upregulation of the DNA methyltransferase DNMT1 ( Figure 4A ). DNMT1 interacts with the methyltransferase G9a to coordinate DNA and H3K9 methylation during cell replication 42 promoting transcriptional silencing of target genes. Moreover, G9a can suppress transcription by inducing DNA methylation in addition to its activity as a chromatin remodeler 43 . In this regard, we hypothesize that the dual inhibition of DNMT1 and G9a could reactivate hypermethylated and silenced genes of MSCs from MM patients preserving their osteogenic potential and therefore preventing myeloma-associated bone loss. Thus, we utilized a dual inhibitor of DNMTs and G9a, termed CM-272, which has been previously described to have a potent therapeutic response, both in vitro and in vivo, in other neoplasias 44454647 .
We first checked the effect of CM-272 on the cell viability of mesenchymal progenitors and we selected a dose (50 nM) with no significant toxicity in order to perform further experiments ( Figure   4B ). CM-272 treatment was able to restore the expression of Homeobox genes (HOX-A6, -A9, -A10, -C9, PITX1 and RUNX2) that were epigenetically repressed in MSCs from MM patients ( Figure 4C) .
Mechanistically, we observed a loss of DNA methylation in the promoter region of the majority of the aforementioned genes after CM-272 treatment in MM-MSCs ( Figure 4D) . We then checked the levels of the inactive chromatin mark H3K9me2, a hallmark of methyltransferase G9a activity, at these gene promoters upon CM-272 treatment. ChIP-qPCR analysis showed a decrease in H3K9me2 levels at the promoter regions of Homeobox genes after CM-272 treatment ( Figure 4E) . Taken together, our results suggest that CM-272 acts in vitro by inhibition of both DNMT and G9a methyltransferase activity.
Next, we addressed whether targeting DNMT and G9a may have a role in regulating osteogenic differentiation. For this purpose, we cultured MSCs from myeloma patients in osteogenic media to obtain differentiated OBs in the presence or absence of CM-272. As observed in Figure 4F and G, CM-272 was able to increase ALP activity in early-stage OBs. Furthermore, CM-272 treatment was able to upregulate the relative expression of several late bone formation markers (namely, bone siaploprotein, osteopontin, and osteocalcin) in MSCs from myeloma patients ( Figure 4H ).
CM-272 not only controls tumor burden but also prevents the myeloma-associated bone loss
To test the effect of CM-272 in the context of MBD, we used an established murine model of bone marrow-disseminated myeloma. After equivalent engraftment of myeloma cells (RPMI8226-luc) was verified by bioluminescence measurement, mice were treated for 4 weeks with CM-272 as described in Methods. Compared with the vehicle control group, CM-272 controlled tumor progression as measured by bioluminescence ( Figure 5A ) or by serum levels of hIgλ secreted by MM cells ( Figure   5B ). Representative microCT images at the metaphyses of distal femurs showed tumor-associated bone loss in vehicle-treated mice, in contrast with trabecular structures observed in CM-272-treated animals ( Figure 5C ). The 3D reconstruction images of distal femurs revealed a marked bone loss evidenced by a thin trabecular network (in red) but also by loss of cortical bone (in grey) in vehicletreated mice ( Figure 5D ). By contrast, CM-272-treated mice presented a gain in both trabecular and cortical bone ( Figure 5D ). This was also reflected by bone morphometric parameters which resulted in increased trabecular bone volume, occupancy and connectivity and reduced trabecular separation in CM-272-treated animals, as compared with vehicle control (Figure 5E ). Finally, these findings correlated with a significant increase in serum levels of the bone formation marker P1NP analyzed after CM-272 treatment compared to untreated control ( Figure 5F) . In summary, these data demonstrate that CM-272 exerts in vivo anti-myeloma activity along with bone anabolic effects in human MM bearing-mice.
To further examine the in vivo effect of CM-272 on DNA methylation of myeloma-associated MSCs, we performed reduced representation bisulfite sequencing (RRBS) analysis of MSCs isolated from vehicle-and CM-272-treated myeloma-bearing mice using healthy mice as controls. First, we observed significant alterations in the DNA methylome of myeloma bearing mice compared to healthy mice ( Supplementary Table S9 ). We then compared the methylation status of hypermethylated CpGs in mice treated with CM-272 and observed a partial reversal of the aberrant hypermethylation ( Figure 5G) . These DNA methylation changes occurred at genomic loci enriched for genes involved in cell commitment and differentiation, such as Homeobox genes ( Figure 5H ). Specifically, we were able to identify CpGs that experienced a gain in DNA methylation in vehicle-treated MSCs compared to healthy controls at the same genomic loci previously identified in human MM-MSCs (HOX-B7, -B9, -D10). Importantly, CM-272 treatment was able to restore the DNA methylation levels at these loci to resemble that of healthy mice, which was concomitant with the reduced tumor burden as well as bone loss recovery observed in these mice. (Figure 5I ).
DISCUSSION
The pathogenic transition from premalignant stages to active MM is complex and not well understood. Deregulation of methylome in MM-MSCs mediates transcriptional and phenotypical alterations. Interestingly, many genes of the Homeobox family displayed both epigenetic and transcriptional dysregulation in patient MSCs, and these changes were observed in earlier stages of disease. In this regard, members of the HOX family have been recently described to be key drivers of OB differentiation, in which their expression is fine-tuned by demethylation of their promoters during the osteogenic process 54 . Furthermore, we observed that healthy MSCs exposed to MM cells, similar to what was observed in patient MSCs, not only displayed an altered methylome, but also showed impaired MSC-to-OB differentiation, as previously described 20 . Hence, our results suggest that the impairment of osteogenesis in all stages of MM arise from early transcriptional deregulation of Homeobox genes, in which altered DNA methylation may be the primary mediator in this process.
One example of this complexity is that although all MM cases
Although the biology of MBD is relatively well-described, there is still a lack of pharmacological treatments to improve bone loss. Clinically approved bone-modifying agents for the treatment of MBD include bisphosphonates 55 , that inhibit bone resorption by suppressing OC activity, and denosumab 56 , a monoclonal antibody against the osteoclastogenic cytokine RANKL. However, these drugs only target the OC compartment, and bone disease still persists due to the absence of bone formation.
Thus, therapeutic agents targeting OBs are needed. In this study, we demonstrate a new strategy for treating MBD by targeting aberrant DNA methylation in MSCs. Firstly, we observed that treatment with CM-272 was able to reverse the transcriptional and epigenetic alterations in MSCs from myeloma patients. Additionally, this agent promotes the ability of MSCs to differentiate into OBs. These in vitro effects on bone were mirrored in a mouse model of disseminated MM. Of note, CM-272 treatment not only prevents bone loss by bone-anabolic effects but also show anti-myeloma activity. This is in line with previous reports showing that DNMTs are targets for the treatment of MM 575859 and also for improving the osteogenic differentiation ability of MSCs 60 . Additionally, we cannot discard the possibility that the observed effects on tumor growth inhibition may be a consequence of the impairment of the cross-talk between MSCs and MM cells. Moreover, the dual targeting effects of CM-272 also inhibit the dimethylation of H3K9, which has been described to be crucial in the establishment of DNA methylation 4243 . It is therefore rational to envision that the bone anabolic effects mediated by CM-272, both in vitro and in vivo, involves the reversion of aberrant hypermethylation at Homeobox loci in the MSC population.
In summary, our findings highlight the existence of aberrant DNA methylation patterns in the BM-derived MSC population which can impact the myeloma progression and development of MBD.
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